Yeon Jung Song

This inventor holds 10 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Hanall Biopharma Co., Ltd., Daewoong Pharmaceutical Co., Ltd., Immunomet Therapeutics Inc.. Active years: 2011-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yeon Jung Song. Retrieved from https://idiyas.com/inventor/yeon-jung-song

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 5)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 8.7

ph-index = 1

Forward Citations = 17(Granted Patents)

Location History:

Yongon-si, KR (2014)
Yongin-si, KR (2015)
Suwon-si, KR (2011 - 2018)
Gyeonggi-do, KR (2014 - 2023)

Company Filing History:

8 out of 27

Hanall Biopharma Co., Ltd.

patents

1 out of 77

Daewoong Pharmaceutical Co., Ltd.

patents

1 out of 17

Immunomet Therapeutics Inc.

patents

Years Active: 2011-2023

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11613578 - Antibody binding to FCRN for treating autoimmune diseases (2023-03-28),

2. 10544226 - Antibody binding to FcRn for treating autoimmune diseases (2020-01-28),

3. 10336825 - Antibody binding to FcRn for treating autoimmune diseases (2019-07-02),

4. 10280207 - FcRn-specific human antibody and composition for treatment of autoimmune diseases (2019-05-07),

5. 10058558 - Pharmaceutical composition comprising N1-cyclic amine-N5-substituted biguanide derivatives as an ingredient for preventing or treating fibrosis (2018-08-28),

6. 9580490 - Uses of modified human tumor necrosis factor receptor-1 polypeptide (2017-02-28),

7. 9068019 - Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same (2015-06-30),

8. 8895500 - Modified human tumor necrosis factor receptor-I polypeptide or fragment thereof, and method for preparing same (2014-11-25),

9. 8754037 - Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same (2014-06-17),

10. 7968579 - Antifungal triazole derivatives (2011-06-28),

Title: Yeon Jung Song: Innovator in Autoimmune Disease Treatment

Introduction

Yeon Jung Song is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of treatments for autoimmune diseases. With a total of 10 patents to his name, his work has the potential to impact many lives.

Latest Patents

One of Yeon Jung Song's latest patents involves an isolated anti-FcRn antibody. This antibody binds to the neonatal Fc receptor (FcRn), which has a high affinity for immunoglobulin G (IgG) or its fragments. The patent describes a method of preparing this antibody, a composition for treating autoimmune diseases that includes the antibody, and methods for treating and diagnosing these diseases. The FcRn-specific antibody binds to FcRn non-competitively with IgG, effectively reducing serum pathogenic auto-antibody levels. This innovative approach can be utilized for the treatment of various autoimmune diseases.

Career Highlights

Throughout his career, Yeon Jung Song has worked with notable companies in the biotechnology sector. He has been associated with Hanall Biopharma Co., Ltd. and Immunomet Therapeutics Inc. His experience in these organizations has contributed to his expertise in developing therapeutic solutions.

Collaborations

Yeon Jung Song has collaborated with several professionals in his field, including Sung Wuk Kim and Seung Kook Park. These collaborations have likely enhanced his research and development efforts.

Conclusion

Yeon Jung Song is a distinguished inventor whose work in antibody development for autoimmune diseases showcases his innovative spirit and dedication to improving healthcare. His contributions are paving the way for new treatment options in the medical field.

Profile summary based on public USPTO records.